Shares in Almirall (BME: ALM) looked set to close nearly 5% higher after Monday’s trading following the firm’s presentation of its 2022 financial results.
The Spanish drugmaker met its guidance with the sales figures, which rose by 5% to 878.5 million euros ($939 million) for the full year, an achievement attributed to the strength of the company’s European dermatology business.
"We are confident that Almirall’s growth drivers will continue their positive trajectory during 2023 while we keep preparing for lebrikizumab’s launch"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze